ReviewJournal of personalized medicine2021
Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Review
- Exploring the Possible Role of Endometriosis-Associated Dysbiosis in Endometrial Carcinogenesis.Medicina (Kaunas, Lithuania) · 2026Review
- Assessing the female urogenital-rectal axis microbiome: focus on endometriosis and recurrent implantation failure.Reproductive biology and endocrinology : RB&E · 2026Article
- Modulation of hormones in perimenopausal women by probiotics associated by specific gut bacteria: a pilot study.Przeglad menopauzalny = Menopause review · 2026Article
- Review
- Bidirectional Communication of Estrogen in Gut-Brain Axis: Evidence from Preclinical and Clinical Studies.Current drug targets · 2026Review
- Uterine microbiota dynamics and new therapeutic opportunities in gynecological diseases.American journal of translational research · 2026Review
- Endometrial Microbiome and Reproductive Receptivity: Diverse Perspectives.International journal of molecular sciences · 2025Review
- Microbiome impacts quality of life in patients with endometrial cancer and benign gynecological conditions.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Plasma metabolites and endometrial cancer: elucidating causal associations through Mendelian randomization.Discover oncology · 2025Article
- The role of the microbiome in endometrial carcinoma: Pathogenesis, biomarkers, and therapeutic prospects.The journal of obstetrics and gynaecology research · 2025Review
- Navigating complexities of polymorphic microbiomes in endometrial cancer.NPJ biofilms and microbiomes · 2025Article
- Article
- Causal Relationship between Gut Microbiota and Endometrial Cancer: A Two-Sample Mendelian Randomization Study.International journal of medical sciences · 2025Article
- Gut and oral microbiota in gynecological cancers: interaction, mechanism, and therapeutic value.NPJ biofilms and microbiomes · 2024Review
- Review
- Polyphenols Influence the Development of Endometrial Cancer by Modulating the Gut Microbiota.Nutrients · 2024Review
- Human microbiomes in cancer development and therapy.MedComm · 2023Review
- ProbioticMicroorganisms · 2023Article
- Commensal Lactobacilli Metabolically Contribute to Cervical Epithelial Homeostasis in a Species-Specific Manner.mSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Endometrial cancer is one of the most common gynaecological malignancies worldwide. Histologically, two types of endometrial cancer with morphological and molecular differences and also therapeutic implications have been identified. Type I endometrial cancer has an endometrioid morphology and is estrogen-dependent, while Type II appears with non-endometrioid differentiation and follows an estrogen-unrelated pathway. Understanding the molecular biology and genetics of endometrial cancer is crucial for its prognosis and the development of novel therapies for its treatment. However, until now, scant attention has been paid to environmental components like the microbiome. Recently, due to emerging evidence that the uterus is not a sterile cavity, some studies have begun to investigate the composition of the endometrial microbiome and its role in endometrial cancer. In this review, we summarize the current state of this line of investigation, focusing on the relationship between gut and endometrial microbiome and inflammation, estrogen metabolism, and different endometrial cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.